The Analyst Landscape: 4 Takes On Roivant Sciences
Portfolio Pulse from Benzinga Insights
Roivant Sciences (NASDAQ:ROIV) received mixed analyst ratings with an average 12-month price target of $15.75, reflecting an 8.62% increase from the previous target. The company showed significant revenue growth of 196.03% as of September 30, 2023, but struggles with profitability and efficiency, indicated by a net margin of -820.27%, ROE of -32.74%, and ROA of -14.48%. Its debt-to-equity ratio stands at 0.52, below industry average.
February 14, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences received mixed analyst ratings, with an updated average 12-month price target of $15.75. The company's significant revenue growth contrasts with its profitability and efficiency challenges.
The mixed analyst ratings with a higher price target suggest optimism about Roivant Sciences' future stock performance, despite current profitability and efficiency issues. The significant revenue growth is a positive indicator, but the challenges in profitability and asset utilization may temper investor enthusiasm. The score reflects the potential for stock price appreciation based on the positive revenue growth and updated analyst targets.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100